MX353319B - Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. - Google Patents

Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.

Info

Publication number
MX353319B
MX353319B MX2013003092A MX2013003092A MX353319B MX 353319 B MX353319 B MX 353319B MX 2013003092 A MX2013003092 A MX 2013003092A MX 2013003092 A MX2013003092 A MX 2013003092A MX 353319 B MX353319 B MX 353319B
Authority
MX
Mexico
Prior art keywords
antibodies
glucagon receptor
compositions
methods relating
receptor antibodies
Prior art date
Application number
MX2013003092A
Other languages
English (en)
Inventor
Yan Hai
Sylvia Hu Shaw-Fen
C Boone Thomas
A Lindberg Richard
Original Assignee
Amgen Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc Star filed Critical Amgen Inc Star
Publication of MX353319B publication Critical patent/MX353319B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente al receptor de glucagón de humano, en donde dicho anticuerpo o dicho fragmento de unión a antígeno del mismo comprende: un dominio variable de la cadena ligera que comprende una región determinante de complementariedad 1 (CDR1) que comprende la secuencia de aminoácido de SEQ ID NO: 14, una CDR2 que comprende la secuencia de aminoácido de SEQ ID NO:50 y una CDR3 que comprende la secuencia de aminoácido de SEQ ID NO: 74 y un dominio variable de la cadena pesada que comprende una CDR1 que comprende la secuencia de aminoácido de SEQ ID NO: 102, una CDR2 que comprende la secuencia de aminoácido de SEQ ID NO: 128, una CDR3 que comprende la secuencia de aminoácido de SEQ IDNO: 169 .
MX2013003092A 2006-09-20 2007-09-19 Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. MX353319B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84620206P 2006-09-20 2006-09-20
US96897707P 2007-08-30 2007-08-30
PCT/US2007/020349 WO2008036341A2 (en) 2006-09-20 2007-09-19 Compositions and methods relating to glucagon receptor antibodies

Publications (1)

Publication Number Publication Date
MX353319B true MX353319B (es) 2018-01-05

Family

ID=39201088

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009003093A MX2009003093A (es) 2006-09-20 2007-09-19 Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
MX2013003092A MX353319B (es) 2006-09-20 2007-09-19 Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009003093A MX2009003093A (es) 2006-09-20 2007-09-19 Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.

Country Status (19)

Country Link
US (2) US7947809B2 (es)
EP (1) EP2074149B1 (es)
JP (1) JP5513888B2 (es)
KR (1) KR20090059161A (es)
CN (1) CN101589062B (es)
AR (1) AR062895A1 (es)
AU (1) AU2007297652B2 (es)
BR (1) BRPI0715017A8 (es)
CA (1) CA2662613C (es)
CL (1) CL2007002668A1 (es)
CR (1) CR10736A (es)
EA (1) EA200970262A1 (es)
ES (1) ES2444012T3 (es)
IL (1) IL197241A0 (es)
MX (2) MX2009003093A (es)
NO (1) NO20091534L (es)
PE (1) PE20080846A1 (es)
TW (1) TW200820985A (es)
WO (1) WO2008036341A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
KR20120056800A (ko) * 2009-09-08 2012-06-04 (주)네오팜 글루글루카곤 수용체에 대한 항체와 이의 사용
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014264295A1 (en) * 2013-05-07 2015-10-29 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015157629A2 (en) * 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
WO2016050867A1 (en) * 2014-10-01 2016-04-07 Medimmune Limited Antibodies to ticagrelor and methods of use
CN111018987B (zh) * 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
EP3236994A1 (en) 2014-12-23 2017-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
KR20170138456A (ko) 2015-04-02 2017-12-15 렘드 바이로테라퓨틱스, 인크 글루카곤 수용체 길항 항체를 이용한 비만 및 비알콜성 지방간 질환 또는 비알콜성 지방간염의 치료 방법
CA2999747A1 (en) 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20190062441A1 (en) * 2015-10-07 2019-02-28 Remd Biotherapeutics, Inc. Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017120261A1 (en) * 2016-01-04 2017-07-13 Remd Biotherapeutics, Inc. Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
CA3036273A1 (en) * 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2019002437A (es) 2016-08-30 2019-10-09 Regeneron Pharma Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
RU2019126781A (ru) * 2017-01-27 2021-03-01 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Белки, связывающие глюкагоновые рецепторы, и способы их применения
KR20190120775A (ko) * 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d 및 cd16에 결합하는 단백질
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
CN107011414B (zh) * 2017-05-31 2020-04-24 浙江省农业科学院 具有降血糖功能的三肽spf及其用途
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
MX2021007444A (es) 2018-12-21 2021-08-05 Jiangsu Hengrui Medicine Co Proteina biespecifica.
WO2020242200A1 (ko) * 2019-05-29 2020-12-03 고려대학교 산학협력단 엔도텔린 수용체 a 결합력이 향상된 항체
MX2022001882A (es) * 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
KR20230142830A (ko) * 2020-12-31 2023-10-11 노바록 바이오테라퓨틱스 리미티드 Tnfr2에 대한 항체 및 이의 용도
WO2022182664A1 (en) * 2021-02-23 2022-09-01 10X Genomics, Inc. A method for epitope binning of novel monoclonal antibodies
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen, Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) * 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) * 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6909031B2 (en) 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
AU2005319382B2 (en) * 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta

Also Published As

Publication number Publication date
US7947809B2 (en) 2011-05-24
WO2008036341A2 (en) 2008-03-27
US20110223160A1 (en) 2011-09-15
WO2008036341A3 (en) 2009-02-05
PE20080846A1 (es) 2008-08-23
EA200970262A1 (ru) 2009-10-30
CN101589062B (zh) 2014-08-20
CN101589062A (zh) 2009-11-25
US8158759B2 (en) 2012-04-17
AR062895A1 (es) 2008-12-10
BRPI0715017A8 (pt) 2018-04-03
BRPI0715017A2 (pt) 2013-05-28
IL197241A0 (en) 2011-08-01
JP2010504331A (ja) 2010-02-12
KR20090059161A (ko) 2009-06-10
NO20091534L (no) 2009-04-28
TW200820985A (en) 2008-05-16
CL2007002668A1 (es) 2008-05-09
EP2074149B1 (en) 2013-11-06
EP2074149A2 (en) 2009-07-01
US20090041784A1 (en) 2009-02-12
MX2009003093A (es) 2009-06-05
JP5513888B2 (ja) 2014-06-04
CA2662613C (en) 2014-01-28
ES2444012T3 (es) 2014-02-21
CR10736A (es) 2009-06-30
CA2662613A1 (en) 2008-03-27
AU2007297652B2 (en) 2012-02-16
AU2007297652A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA201270634A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ
MX2008009886A (es) Anticuerpos que enlazan par-2.
MY149630A (en) Antibodies against amyloid-beta peptide
MY187263A (en) Il-17 reception a antigen binding proteins
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
PL1972637T3 (pl) Antagoniści selektywni wobec huTNFR1
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
WO2009090656A3 (en) Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
WO2010023482A3 (en) Therapeutic antibody
EA201290630A1 (ru) Лечение расстройства обмена веществ
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
WO2010122135A3 (en) Use of mixed lineage like kinase polypeptides (mlkl polypeptides) in cancer therapy
UA100531C2 (ru) Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp)
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
EA201991493A3 (ru) Антиген-связывающие белки человека, которые связываются с β-клото, рецепторами fgf и их комплексами
UA97414C2 (ru) Выделенное человеческое антитело, связывающееся с gm-csf